other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at [https://www.federalreserve.gov/foia/](https://www.federalreserve.gov/foia/). Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than March 4, 2021.

A. Federal Reserve Bank of Dallas (Robert L. Trillett III, Senior Vice President) 2200 North Pearl Street, Dallas, Texas 75201–2272:

1. VeraBank, Inc., Henderson, Texas; to acquire Panola National Bank, Carthage, Texas.


Michele Taylor Fennell, Deputy Associate Secretary of the Board.

[FR Doc. 2021–02148 Filed 2–1–21; 8:45 am]

BILLING CODE P

### FEDERAL TRADE COMMISSION

Revised Jurisdictional Thresholds for Section 7A of the Clayton Act

**AGENCY:** Federal Trade Commission.

**ACTION:** Notice.

**SUMMARY:** The Federal Trade Commission announces the revised thresholds for the Hart-Scott-Rodino Antitrust Improvements Act of 1976 required by law.

**DATES:** March 4, 2021.

**FOR FURTHER INFORMATION CONTACT:** Nora Whitehead (202–326–3100), Bureau of Competition, Premerger Notification Office, 400 7th Street SW, Room 5301, Washington, DC 20224.

### SUPPLEMENTARY INFORMATION:

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, Public Law 94–435, 90 Stat. 1390 (“the Act”), requires all persons contemplating certain mergers or acquisitions, which meet or exceed the jurisdictional thresholds in the Act, to file notification with the Commission and the Assistant Attorney General and to wait a designated period of time before consummating such transactions. Section 7A(a)(2) requires the Federal Trade Commission to revise those thresholds annually, based on the change in gross national product, in accordance with Section 8(a)(5). Note that while the filing fee thresholds are revised annually, the actual filing fees are not similarly indexed and, as a result, have not been adjusted for inflation in over a decade. The new thresholds, which take effect 30 days after publication in the Federal Register, are as follows:

<table>
<thead>
<tr>
<th>Subsection of 7A</th>
<th>Original threshold (million)</th>
<th>Adjusted threshold (million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7A(a)(2)(A)</td>
<td>$200</td>
<td>$368</td>
</tr>
<tr>
<td>7A(a)(2)(B)(i)</td>
<td>50</td>
<td>92</td>
</tr>
<tr>
<td>7A(a)(2)(B)(ii)</td>
<td>200</td>
<td>368</td>
</tr>
<tr>
<td>7A(a)(2)(B)(iii)</td>
<td>10</td>
<td>18.4</td>
</tr>
<tr>
<td>7A(a)(2)(B)(iv)</td>
<td>100</td>
<td>184</td>
</tr>
<tr>
<td>7A(a)(2)(B)(v)</td>
<td>10</td>
<td>18.4</td>
</tr>
<tr>
<td>7A(a)(2)(B)(vi)</td>
<td>100</td>
<td>184</td>
</tr>
<tr>
<td>7A(a)(2)(B)(vii)</td>
<td>100</td>
<td>184</td>
</tr>
<tr>
<td>Section 7A note: Assessment and Collection of Filing Fee^{1} (3)(b)(1)</td>
<td>100</td>
<td>184</td>
</tr>
<tr>
<td>Section 7A note: Assessment and Collection of Filing Fees (3)(b)(2)</td>
<td>100</td>
<td>184</td>
</tr>
<tr>
<td>Section 7A note: Assessment and Collection of Filing Fees (3)(b)(3)</td>
<td>500</td>
<td>919.9</td>
</tr>
<tr>
<td>Section 7A note: Assessment and Collection of Filing Fees (3)(b)(3)</td>
<td>500</td>
<td>919.9</td>
</tr>
</tbody>
</table>

Any reference to these thresholds and related thresholds and limitation values in the HSR rules (16 CFR parts 801–803) and the Antitrust Improvements Act Notification and Report Form (“the HSR Form”) and its Instructions will also be adjusted, where indicated by the term “(as adjusted)”, as follows:

<table>
<thead>
<tr>
<th>Original threshold (million)</th>
<th>Adjusted threshold (million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10 million</td>
<td>18.4</td>
</tr>
<tr>
<td>$50 million</td>
<td>92</td>
</tr>
<tr>
<td>$100 million</td>
<td>184</td>
</tr>
<tr>
<td>$110 million</td>
<td>202.4</td>
</tr>
<tr>
<td>$200 million</td>
<td>368</td>
</tr>
<tr>
<td>$500 million</td>
<td>919.9</td>
</tr>
<tr>
<td>$1 billion</td>
<td>1,839.8</td>
</tr>
</tbody>
</table>

^{1} Public Law 106–553, Sec. 630(b) amended Sec. 18a note.

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting:

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Date: April 27, 2021.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107–8, Atlanta, Georgia 30341, Telephone (770) 488–6511, JRaman@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kaalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021–02161 Filed 2–1–21; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—PAR 20–297, NIOSH Centers of Excellence for Total Worker Health (TWI).
Date: April 26–29, 2021.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Michael Goldcamp, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1995 Willowdale Road, Morgantown, West Virginia 26505, Telephone (304) 285–5951, MGoldcamp@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kaalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021–02162 Filed 2–1–21; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—SIP21–004, Development, Evaluation and Dissemination of an Evidence-Based Intervention to Increase Sun Safety among Outdoor Workers.
Date: May 4, 2021.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.